Objective:
To assess the link between GLP-1 agonists and diabetic retinopathy (DR) and its implications for clinical practice, particularly in monitoring and screening.
Key Findings:
- Dulaglutide and semaglutide are strongly associated with worsening DR, indicating a need for careful monitoring.
- Liraglutide and tirzepatide show a weaker but significant link to DR, warranting attention in clinical practice.
- Lixisenatide has no major link with DR, suggesting it may be a safer option for patients with existing DR.
Interpretation:
The association between GLP-1 agonists and DR may be due to improved glycemic control, which can temporarily worsen DR, similar to insulin effects, highlighting the need for careful patient management.
Limitations:
- Further studies are needed to clarify the long-term effects of GLP-1 agonists on DR, particularly in diverse populations.
- Current findings are based on adverse event reports, which may not capture all cases, indicating a need for more comprehensive data collection.
Conclusion:
Optometrists should monitor patients on GLP-1 agonists closely for DR progression and consider more frequent screenings, especially for those with existing DR or recent vision changes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.